EATG » Hepatitis

Hepatitis

Euro-Canadian study looks at trends in liver cancer in co-infected people

Hepatitis C virus (HCV) and HIV have shared routes of infection. As a result, some people have both infections. This state is called co-infection. HCV infects the liver, and in…

FDA approves Gilead’s Epclusa® for the treatment of all genotypes of chronic hepatitis C

Epclusa is the first and only all-oral, pan-genotypic single tablet regimen for chronic hepatitis C virus infection and Gilead’s third sofosbuvir-based regimen FOSTER CITY, Calif.--Jun. 28, 2016-- Gilead Sciences, Inc.…

Gilead’s new hepatitis C drug approved by FDA, priced at $74,760

Epclusa is first treatment for all forms of the disease Drug will mainly be used in patients with genotypes 2 and 3 Gilead Sciences Inc.’s hepatitis C drug was approved…

Regulus reports clinical hold of RG-101

Timelines of on-going studies are not expected to be impacted LA JOLLA, Calif., June 27, 2016 -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of…

Baraclude therapy for HBV leads to lower than expected HCC incidence

Patients with hepatitis B virus infection treated with Baraclude had an unexpected lower incidence of hepatocellular carcinoma over time, although the risk for hepatocellular carcinoma in this patient population still…

First HBV patient dosed in the ACHIEVE Phase 2 program of SB 9200

Phase 2a study to evaluate SB 9200 monotherapy followed by sequential dosing with Viread in 80 treatment-naïve HBV patients HOPKINTON, Mass., June 22, 2016 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH),…

Strategies for improving the hepatitis C care continuum for people who inject drugs

Hepatitis C treatment has changed dramatically in the past few years, with the development of medications that have cure rates of 90% and greater, few side effects and short durations,…

Hepatitis C antigen testing could eliminate need for two-step HCV testing, reduce cost of access

Testing for hepatitis C virus core antigen could eventually replace the current two-step procedure for diagnosing chronic hepatitis C infection in lower- and middle-income countries, speeding up access to treatment…

ContraVir doses first patients in head-to-head study of CMX157 vs. Viread® for treating hepatitis B

Advances to final 100 mg dosing group in Phase 1b volunteer study EDISON, N.J., June 21, 2016 -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and…

Immunizing infants against hepatitis B tied to lower risk of liver cancer

Immunizing infants against hepatitis B virus (HBV) appears to reduce their risk of developing hepatocellular carcinoma as children or young adults, according to a study from Taiwan. "Clinicians should advise…